Member Info for BuenaVista

Well said Rooba, although pointless posting it in this pointless thread.

I see grants to foreign companies to come here and buy up British businesses.

Thank you RitchieG01. That could well cause investors to take fright.

Biden zeroes in on drug costs during State of the Union address

President Joe Biden targeted high prescription drug costs Tuesday night in his State of the Union address, in addition to touching on other healthcare issues including the opioid crisis, abortion, Medicare solvency, surprise billing and more.

He called for extending Medicare's $35 insulin price cap to all Americans and blasted “big pharma” for record profits while at the same time “unfairly charging people hundreds of dollars.”

“For example, too many of you lay in bed at night staring at the ceiling, wondering what will happen if your spouse gets cancer, your child gets sick, or if something happens to you,” he said in prepared remarks. “Will you have the money to pay your medical bills? Will you have to sell the house?”

His remarks aligned with those from incoming Senate health committee chairman Sen. Bernie Sanders, I-Vt., who said earlier this year the pharmaceutical industry’s actions “are literally killing Americans.”

Biden said he would veto any threats to the government’s recent measures to rein in drug spending through the Inflation Reduction Act and any proposals for a nationwide abortion ban.

https://www.healthcaredive.com/news/biden-drug-costs-during-state-of-the-union/642300/

I've got to agree. US healthcare costs are stupidly high. The land of the fee.

An interesting topic JT. I'll have a go at answering parts at least, plus raising some considerations.

1.
AVA6000 has a different TAM from standard doxorubicin in two important respects: Firstly AVA6000, like all pre|CISION substrates only works in FAPa-rich cancers; that is not a consideration for using standard doxorubicin. Secondly, AVA6000 will have certain contraindications where there is a high level of FAPa in other, 'healthy' tissues such as fibrosis, inflammation and soon after major surgery or injury.

2.
Doxorubicin is in the anthracycline class of drugs - drugs that all have the same basic mechanism of action. Is there any reason why AVA6000 shouldn't replace all anthracyclines, subject to (1) above being satisfied? I don't think so. Add this to older people and people in poor health being treatable by an anticancer 'without' side effects and the AVA6000 TAM is enormous.

3.
AVA3996 was first worked on by Arisaph Pharmaceuticals in Boston, where it was given the research code ARI-3996 and exemplified in patents (e.g. US9597410B2).
Another chemical entity worked on by that company was ARI-3099DOX, also called just 3099DOX when exemplified in patents (e.g. WO2015192123A1) and ARI-6000. Now commonly known as AVA6000.
https://fundedresearch.cancer.gov/nciportfolio/search/details;jsessionid=A74DE699A48D0D1B0E898E2563A05FB1?action=abstract&grantNum=2R42CA156930-02&grantID=8714288&grtSCDC=FY%202014&absID=8714288&absSCDC=PUB2014
I'm not aware of Arisaph exemplifying any others. Hopefully they have been exemplified in Bachovchin's patents!

4.
To become a pre|CISION substrate, an anticancer drug needs to be able to form a peptide bond with 5140 (the leaving group), which can subsequently be cleaved by FAPa. From a conformational point of view - a 3D structure that can get in close to the FAP enzyme so that cleavage can take place - the drug would ideally have an exposed free amine (-NH2) group, as doxorubicin has. Velcade has a -NH- group in a ring but no -NH2 group and, as AVA3996 is described an a Velcade analogue, I assume that the peptide bond can't be formed with that -NH- in the ring, so a -NH2 group has been added somewhere in order to form the peptide bond with 5140. A peptide bond could be formed using the -NH- but, as an analogue has been made, I assume the resultant peptide bond couldn't be cleaved by FAP because of conformational (3D structure) issues. As an analogue it is a new chemical entity and so would require full testing for toxicity and efficacy.
These conditions will apply to all the pre|CISION pipeline: a free -NH2 group for the prodrug, otherwise an -NH2 group added and so an analogue; and the drug needs to have a 3D structure that allows the peptide bond to get close to FAP's cleaving site (so, as a general rule of thumb, small structures favoured over bulky ones). As an analogy, a key with a long handle works a lock but a key with a barrel wider than the keyhole won't.

Biotech took a tumble on NASDAQ yesterday after Fed comments on inflation.
https://www.proactiveinvestors.com/companies/news/1005547/s-p-500-nasdaq-dow-slump-on-poor-earnings-results-wednesday-as-fed-fueled-rally-fades-1005547.html

LSE is a bit funny about these things, so if the URL gets the *** treatment:
p r o a c t i v e i n v e s t o r s

Also, SPs don't go up in a straight line!

Is that a reference to the bad end of Kings Cross?

Why do people who know the square of f all about pharmaceutical development feel the need to comment on how drug trials should be carried out?

There is a PROCESS and that process takes TIME in order to find the most EFFICACIOUS DOSING REGIMEN for each CONDITION.

Professional people with respected reputations do this. It is their work and their reputation. They do not, as some here purport to say should happen, go round randomly injecting random patients with random quantities of a new drug that has shown early promise.

Thanks for the link

You have no concept of medical ethics. In the bin you go.

Avacta fell out of the UK Small Cap index, or whichever one has companies larger than Micro Cap.

Well stop standing behind MrR

Also, Avacta continues to make its way up the Largest pharma companies by market cap listing from beyond 300 to now 273rd, catching POINT Biopharma, currently at 237th.
https://companiesmarketcap.com/pharmaceuticals/largest-pharmaceutical-companies-by-market-cap/?page=3

I know. It's so unbelievable that I've finally hit on not just a winner, but a miraculous winner, I have to pinch myself.

Was that my green box? You should try it - saves all the need for posts like yours.

Currently down 10% today, up 6% for the week. Up 23% last week.

Here's news to you Senza:@ share prices don't move in a straight line.

Trader. Filtered.

L'eagle

I think more than news of DE4, the reason for the delay in doing the dose escalation will be in an RNS if a DE is allowed before or on Science Day. Avacta are not obliged to announce DEs are they?

I'm not expecting a programmes update until 7am on Science Day, and even then I'm not expecting anything more than the slides that will be shown to the attendees and so without the nuances, nods and woinks that those in the room will get, just like happened with the AGM.

News outside Avacta's control may happen at any time before Science Day though - milestone payments, TR1s, licence agreements (although Avacta could arrange to delay those until Science Day).

To note: the American markets are closed on Monday, 20th for Presidents' Day.

What's the latest theory then?

Yes, good news to be advertising for a Supply Chain Manager but... someone really should have proofread the job description.